Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences
- PMID: 10796051
- DOI: 10.1007/s004230050255
Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences
Abstract
Diagnostic imaging for suspected tumour recurrence of primary colorectal cancer frequently lacks specificity and sensitivity. The impact of whole body 18F-FDG-positron-emission tomography (PET) on detection of local recurrences and hepatic or pulmonary metastases was evaluated in a prospective study. Results were compared with computed tomography (CT), ultrasonography, magnetic resonance imaging and conventional chest X-ray. The study included 71 patients (77 investigations) with suspected local recurrence, hepatic metastases or unexplained raised level of the tumour marker carcinoembryonic antigen (CEA). The results demonstrate that 18F-FDG-PET was clearly superior to CT with regard to detection of hepatic metastases. Sensitivity was 1.0 and specificity 0.98 compared with 0.87 and 0.91 for CT. In four cases, 18F-FDG-PET clarified otherwise unclear local recurrences. In five patients, 18F-FDG-PET showed pulmonary metastases that had previously been unknown. In a total of 16 patients (20.8%), 18F-FDG-PET provided additional information leading to a change of the treatment strategy. 18F-FDG-PET clearly has the ability to detect colorectal tumour recurrence and its metastases in a whole body format. Therefore, it may be applied in the follow-up of patients with primary colorectal cancer. Despite the costs, it is certainly recommended for patients with an otherwise unclear increase of CEA level or with unproven local recurrence.
Similar articles
-
Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.Hepatogastroenterology. 2006 May-Jun;53(69):348-50. Hepatogastroenterology. 2006. PMID: 16795969
-
FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.J Nucl Med. 2000 Oct;41(10):1657-63. J Nucl Med. 2000. PMID: 11037995
-
Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.Anticancer Res. 2001 Mar-Apr;21(2B):1375-8. Anticancer Res. 2001. PMID: 11396217
-
The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.Cancer. 2005 Dec 15;104(12):2658-70. doi: 10.1002/cncr.21569. Cancer. 2005. PMID: 16315241 Review.
-
[Imaging in the diagnosis of colorectal liver metastases and extrahepatic abnormalities].Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):857-62. Ned Tijdschr Geneeskd. 2008. PMID: 18512524 Review. Dutch.
Cited by
-
A case of plastron appendicitis mimicking malignant cecal tumor in flourodeoxyglucose-positron emission tomography/computed tomography study.Indian J Nucl Med. 2015 Jul-Sep;30(3):256-8. doi: 10.4103/0972-3919.151653. Indian J Nucl Med. 2015. PMID: 26170571 Free PMC article.
-
The Use of PET-CT in the Assessment of Patients with Colorectal Carcinoma.Int J Surg Oncol. 2011;2011:846512. doi: 10.1155/2011/846512. Epub 2011 Jul 3. Int J Surg Oncol. 2011. PMID: 22312527 Free PMC article.
-
FDG-PET in colorectal cancer.Cancer Imaging. 2006 Oct 31;6(Spec No A):S71-81. doi: 10.1102/1470-7330.2006.9014. Cancer Imaging. 2006. PMID: 17114081 Free PMC article.
-
Role of PET/CT in the detection of liver metastases from colorectal cancer.Radiol Med. 2009 Jun;114(4):571-85. doi: 10.1007/s11547-009-0393-7. Epub 2009 May 14. Radiol Med. 2009. PMID: 19444590 English, Italian.
-
Comparison of MRI (including SS SE-EPI and SPIO-enhanced MRI) and FDG-PET/CT for the detection of colorectal liver metastases.Eur Radiol. 2009 Feb;19(2):370-9. doi: 10.1007/s00330-008-1163-y. Epub 2008 Sep 16. Eur Radiol. 2009. PMID: 18795299
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical